Biodostępność: czynniki wpływające

Physicochemical properties like poor solubility significantly decrease drug absorption and reduce bioavailability. Specialized formulations such as controlled-release or enteric-coated forms can address these limitations. For example, Neoral® microemulsion enhances cyclosporine bioavailability compared to conventional formulations by improving dissolution and absorption rates.

Acid-labile drugs degrade in the low pH environment of the stomach, significantly reducing bioavailability. Buffered or enteric-coated formulations protect these drugs from gastric acidity, maintaining therapeutic levels. Didanosine uses these strategies to prevent degradation and ensure adequate systemic exposure for therapeutic benefit.

First-pass metabolism occurs when drugs are extensively metabolized in the liver during their first pass through portal circulation, significantly reducing systemic availability. Propranolol undergoes extensive first-pass metabolism, reducing its systemic exposure. Prodrugs like valacyclovir bypass this limitation by converting to active forms after absorption, enhancing bioavailability.

Food can enhance, reduce, or have no significant impact on drug bioavailability. Food increases isotretinoin absorption but reduces didanosine bioavailability. Drug-drug interactions also affect bioavailability through metabolizing enzymes: enzyme inhibitors like ritonavir increase systemic levels by slowing metabolism, while inducers like rifampin accelerate it, reducing plasma concentrations.

Transport proteins such as P-glycoprotein significantly influence drug absorption and clearance. Drugs that inhibit or are substrates for transport proteins, like digoxin, show variable bioavailability depending on transporter activity. Understanding transporter interactions is essential for predicting drug exposure and optimizing therapeutic outcomes.

Aging alters bioavailability through reduced liver mass, decreased perfusion, and declining renal function, potentially increasing drug levels in geriatric patients. Renal and hepatic impairments significantly affect drug elimination: renally excreted drugs show increased bioavailability in kidney dysfunction, while hepatic impairment reduces metabolism, causing systemic drug accumulation.

Multiple strategies overcome bioavailability challenges. Controlled-release and enteric-coated formulations improve solubility and protect from gastric degradation. Prodrug design enhances absorption by converting to active forms post-absorption. Understanding bioavailability enhancement determination and conceptual approaches helps optimize formulations, dosing regimens, and therapeutic outcomes for effective patient care.